
(trye mi’ pra meen)
Apo-Trimip (CAN), Surmontil
PREGNANCY CATEGORY C
Drug Classes
Antidepressant
TCA (tertiary amine)
Therapeutic Actions
Mechanism of action unknown; the TCAs are structurally related to the phenothiazine antipsychotics (eg, chlorpromazine); TCAs inhibit the presynaptic reuptake of the neurotransmitters norepinephrine and serotonin; anticholinergic at CNS and peripheral receptors; the relation of these effects to clinical efficacy is unknown.
Indications
Relief of symptoms of depression (endogenous depression most responsive); sedative effects of tertiary amine TCAs may be helpful in patients whose depression is associated with anxiety and sleep disturbance
Unlabeled use: Duodenal ulcers
Contraindications and Cautions
Contraindicated with hypersensitivity to any tricyclic drug, concomitant therapy with an MAOI, recent MI, myelography within previous 24 hr or scheduled within 48 hr, pregnancy (limb reduction abnormalities may occur), lactation.
Use cautiously with EST; pre-existing CV disorders (eg, severe CAD, progressive HF, angina pectoris, paroxysmal tachycardia); angle-closure glaucoma, increased IOP; urinary retention, ureteral or urethral spasm (anticholinergic effects of TCAs may exacerbate these conditions); seizure disorders (TCAs lower the seizure threshold); hyperthyroidism (predisposes to CVS toxicity, including cardiac arrhythmias); impaired hepatic, renal function; psychiatric patients (schizophrenic or paranoid patients may exhibit a worsening of psychosis); patients with bipolar disorder (may shift to hypomanic or manic phase); elective surgery (TCAs should be discontinued as long as possible before surgery).
Available Forms
Capsules—25, 50, 100 mg
Dosages
Adults
Hospitalized patients: Initially, 100 mg/day PO in divided doses. Gradually increase to 200 mg/day as required. If no improvement in 2–3 wk, increase to a maximum dose of 250–300 mg/day.
Outpatients: Initially, 75 mg/day PO in divided doses. May increase to 150 mg/day. Do not exceed 200 mg/day. Total daily dosage may be administered at bedtime. Maintenance dose is 50–150 mg/day given as a single dose at bedtime. After satisfactory response, reduce to lowest effective dosage. Continue therapy for 3 mo or longer to lessen possibility of relapse.
Pediatric patients 12 yr and older
50 mg/day PO with gradual increases up to 100 mg/day.
Pediatric patients younger than 12 yr
Not recommended.
Geriatric patients
50 mg/day PO with gradual increases up to 100 mg/day PO.

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

